ASLAN Pharmaceuticals Limited and Thermo Fisher Scientific Inc. announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile for the treatment of moderate-to-severe atopic dermatitis (AD). ASLAN has developed a high concentration formulation of eblasakimab, allowing up to 400mg eblasakimab to be administered in a single subcutaneous injection and suitable for use with different devices.

Thermo Fisher plans to commence manufacturing the new formulation in its commercial-scale Good Manufacturing Practices (GMP) certified manufacturing facilities in January 2023. ASLAN is conducting the TREK-AD trial, a global randomized, double-blind, placebo-controlled, dose-ranging, Phase 2b clinical trial, to evaluate the efficacy and safety of eblasakimab in adult patients with moderate-to-severe AD. Topline data from this trial is expected in the second quarter of 2023.

The company is also conducting the TREK-DX study to evaluate eblasakimab in adult patients with moderate-to-severe AD who have previously been treated with dupilumab. Topline data from the TREK-DX study is expected in the first quarter of 2024.